MARKET

TNGX

TNGX

Tango Therapeutics Inc
NASDAQ
9.23
-0.12
-1.28%
Opening 12:56 12/15 EST
OPEN
9.52
PREV CLOSE
9.35
HIGH
10.08
LOW
9.08
VOLUME
1.73M
TURNOVER
--
52 WEEK HIGH
11.20
52 WEEK LOW
1.030
MARKET CAP
1.24B
P/E (TTM)
-10.0239
1D
5D
1M
3M
1Y
5Y
1D
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Barchart · 3d ago
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect?
NASDAQ · 12/08 14:55
Weekly Report: what happened at TNGX last week (1201-1205)?
Weekly Report · 12/08 09:34
Tango Therapeutics Price Target Announced at $15.00/Share by Stifel
Dow Jones · 12/04 17:09
Tango Therapeutics Initiated at Buy by Stifel
Dow Jones · 12/04 17:09
Stifel Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $15
Benzinga · 12/04 16:58
U.S. RESEARCH ROUNDUP-Fiserv, PayPal, UMH Properties
Reuters · 12/04 07:52
Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics’ Vopimetostat
TipRanks · 12/03 21:27
More
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

Webull offers Tango Therapeutics Inc stock information, including NASDAQ: TNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNGX stock methods without spending real money on the virtual paper trading platform.